Showing 828 results
-
Media Release /Scemblix, a new first-line option for adults with CML, is first to show superior efficacy and favorable safety and tolerability profile in a Phase III trial vs. all standard of care (SoC)…
-
Media Release /New APPEAR-C3G data show Fabhalta sustained proteinuria reduction at 12 months1Upon Fabhalta initiation, improvement observed in estimated glomerular filtration rate (eGFR) slope – a key measure of…
-
Media Release /Longer-term 96-week results from Scemblix® ASC4FIRST Phase III study in first-line Ph+ CML-CP to be presented following recent FDA approval based on 48-week data Late-breaking Kisqali®* 4-…
-
Story /As Novartis expands its manufacturing capabilities, our new Carlsbad facility will help deliver time-sensitive cancer treatments to patients, meeting future demand.
-
Biography /
-
Biography /
-
Media Release /Expansion represents significant investment in North Carolina and is expected to create 700 new jobs in the state by end of 2030Enables manufacturing of medicines across company’s main therapeutic…
-
Story /Learn how community-driven partnerships are helping to break down barriers and support access to health care.
-
Biography /
